financetom
Business
financetom
/
Business
/
Furniture maker La-Z-Boy Q1 sales miss estimates
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Furniture maker La-Z-Boy Q1 sales miss estimates
Aug 20, 2025 3:58 AM

Overview

* La-Z-Boy ( LZB ) fiscal Q1 sales fall 1%, missing analyst expectations, per LSEG data

* Adjusted EPS for fiscal Q1 misses consensus, per LSEG data

Outlook

* La-Z-Boy ( LZB ) expects Q2 sales between $510 mln and $530 mln

* Company projects Q2 adjusted operating margin of 4.5% to 6.0%

Result Drivers

* RETAIL GROWTH - Retail segment written sales increased 5% driven by new and acquired stores, while delivered sales rose 2%

* WHOLESALE PERFORMANCE - Wholesale segment delivered sales grew 1%, driven by core North America La-Z-Boy wholesale business

* JOYBIRD DECLINE - Joybird sales decreased due to lower delivered sales and a significant customer transition in international wholesale business

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Sales Miss $492 mln $494 mln

(3

Analysts

)

Q1 Miss $0.47 $0.55 (3

Adjusted Analysts

EPS )

Q1 EPS $0.44

Q1 4.8%

Adjusted

Operatin

g Margin

Q1 4.5%

Operatin

g Margin

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the home furnishings peer group is "hold"

* Wall Street's median 12-month price target for La-Z-Boy Inc ( LZB ) is $46.00, about 16.7% above its August 18 closing price of $38.34

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 12 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Blackstone to Buy Paris Office Building for $815 Million
Market Chatter: Blackstone to Buy Paris Office Building for $815 Million
Sep 3, 2025
06:48 AM EDT, 09/03/2025 (MT Newswires) -- Blackstone (BX) has agreed to acquire the Centre d'Affaires office building in Paris for roughly 700 million euros ($814.7 million) from Union Investments, Reuters reported Wednesday. The deal is expected to close in Q4, according to the report. (Market Chatter news is derived from conversations with market professionals globally. This information is believed...
Court Ruling in DOJ Case Removes 'Overhang' on Apple Stock, 'Broadly Favorable' for Google, Wedbush Says
Court Ruling in DOJ Case Removes 'Overhang' on Apple Stock, 'Broadly Favorable' for Google, Wedbush Says
Sep 3, 2025
06:48 AM EDT, 09/03/2025 (MT Newswires) -- Apple ( AAPL ) and Alphabet (GOOGL) scored a massive win in Google's ( GOOG ) antitrust case, with a federal court ruling that their $20 billion search deal will remain in place, Wedbush said in separate notes Tuesday. The decision removes a huge overhang on Apple's ( AAPL ) stock and lays...
Collective Mining Details a New Greenfield Silver Discovery at X Target; Shares at 52 Week Highs In Both Canada and the U.S.
Collective Mining Details a New Greenfield Silver Discovery at X Target; Shares at 52 Week Highs In Both Canada and the U.S.
Sep 3, 2025
06:50 AM EDT, 09/03/2025 (MT Newswires) -- Collective Mining ( CNL ) , trading at 52 week highs in both Canada and the United States, announced Wednesday assay results for 11 diamond drill holes which include a new greenfield silver-rich discovery at the X target, positive infill results at the Apollo system and the interception of moderately grading CBM veins...
Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs
Novartis signs up to $5.2 billion licensing deal with Argo Biopharmaceutical for heart drugs
Sep 3, 2025
Sept 3 (Reuters) - Swiss drugmaker Novartis has signed a licensing and options deal with Argo Biopharmaceutical for up to $5.2 billion to gain access to its experimental cardiovascular drugs, the privately held biotech said on Wednesday. (Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli) ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved